Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1902358 | 0.88 | SMN1; SMN2 (0.76) | ALDH1A1SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL28007665 | 0.86 | SMN1; SMN2 (0.61) | ALDH1A1SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL10255967 | 0.85 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL9144175 | 0.85 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL2525981 | 0.85 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL20875979 | 0.83 | KMT2A (0.57) | ALDH1A1SMN1; SMN2HTTHPGDLMNA | |
| SCHEMBL9437311 | 0.82 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL9437361 | 0.81 | L3MBTL1 (0.64) | ALDH1A1SMN1; SMN2HTTLMNANPC1 | |
| SCHEMBL14966487 | 0.81 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2HTTLMNANPC1 | |
| SCHEMBL5970008 | 0.81 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2HTTTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-11-23 | — | — | US | disclosed |
| US-11180479-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-11-23 | — | — | US | disclosed |
| EP-3692035-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2020-08-12 | — | — | EP | disclosed |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2020-07-30 | — | — | US | disclosed |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2020-07-30 | — | — | US | disclosed |
| WO-2019068841-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | PLA2G1B, PLA2G4A, PLA2G4C | ALDH1A1 2141/4885SMN1; SMN2 504/4885HTT 3151/4885 |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G4A, PLA2G4C | ALDH1A1 2141/4885SMN1; SMN2 504/4885HTT 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.